Oxford BioDynamics (OBD) AI Stock Analysis

• Market Cap: £7.83M
• Dividend Yield: N/A
• Average Volume (3M): 12.73M
• Price to Earnings (P/E): ―
• Beta (1Y): -1.61
• Revenue Growth: 24.71%
• EPS Growth: 38.28%
• Country: UK
• Employees: 51
• Sector: Healthcare
• Sector Strength: 41
• Industry: Biotechnology
• EPS (TTM): -0.02
• Shares Outstanding: 1,957,577,600
• 10 Day Avg. Volume: 14,068,578
• 30 Day Avg. Volume: 12,731,456
• PEG Ratio: >-0.01
• Price to Book (P/B): 0.24
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.38
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 50 Neutral
• Price Target: 0.50p ▲(25.00%Upside)

The overall score is influenced primarily by financial challenges and unattractive valuation metrics, despite positive corporate events. Technical indicators show mixed signals, adding uncertainty to the stock's short-term outlook.

Oxford BioDynamics Business Overview & Revenue Model

Company Description

Oxford BioDynamics (OBD) is a biotechnology company specializing in the development of precision medicine tests based on epigenetic biomarkers. The company operates within the healthcare and life sciences sectors, focusing on the use of its proprietary EpiSwitch technology platform to create diagnostic and prognostic solutions. These solutions aim to improve patient outcomes by offering personalized healthcare insights in areas such as oncology, immunotherapy, and chronic diseases.

How the Company Makes Money

Oxford BioDynamics generates revenue through the commercialization of its EpiSwitch technology. The company licenses its biomarker discovery and testing capabilities to pharmaceutical companies and healthcare providers, enabling them to develop personalized medicine solutions and improve clinical trial outcomes. Additionally, OBD offers its own suite of diagnostic tests directly to healthcare providers and patients, further expanding its revenue streams. Key partnerships with major pharmaceutical companies enhance its market reach and provide substantial collaboration opportunities, contributing significantly to its earnings. The company's revenue model also includes service agreements for biomarker discovery and validation projects, as well as potential royalties from products developed using OBD's technology.

Oxford BioDynamics Financial Statement Overview

Summary

Oxford BioDynamics faces substantial financial challenges with consistent net losses, rising leverage, and negative cash flows. Although there are some assets and equity, these are diminishing, indicating potential liquidity and solvency concerns.

Income Statement

Oxford BioDynamics shows a challenging financial trajectory with consistent net losses over the past years. The gross profit margin is low, and net income has been negative, indicating unprofitability. Revenue growth has been erratic, with no clear upward trend. EBIT and EBITDA margins are negative, reflecting operational inefficiencies and high costs relative to revenue.

Balance Sheet

The balance sheet presents concerns, particularly in rising debt levels relative to equity, which has led to a rising debt-to-equity ratio. Return on equity is negative due to consistent net losses, and the equity ratio has decreased, indicating increased leverage and financial risk. However, there is still some equity cushion available, albeit shrinking.

Cash Flow

Cash flow analysis indicates significant strains with negative free cash flow and operating cash flow over the years. There was a notable decline in free cash flow growth rate, highlighting cash generation issues. Operating cash flow to net income ratio is negative, reinforcing operational cash challenges. Financing activities have been critical in supporting cash needs.

Breakdown
TTM	Sep 2024	Sep 2023	Sep 2022	Sep 2021	Sep 2020
Income Statement		Total Revenue
617.00K	636.00K	510.00K	154.00K	341.00K	456.00K
	Gross Profit
-7.49M	289.00K	266.00K	116.00K	-557.00K	-166.00K
	EBIT
-12.43M	-12.89M	-11.03M	-8.60M	-7.51M	-4.95M
	EBITDA
-9.32M	-10.27M	-9.84M	-6.16M	-6.43M	-4.42M
	Net Income Common Stockholders
-11.11M	-11.57M	-10.83M	-6.71M	-6.68M	-4.31M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
1.19M	2.83M	5.25M	999.00K	4.34M	11.51M
	Total Assets
11.07M	12.11M	16.13M	11.34M	15.38M	15.35M
	Total Debt
6.00M	5.74M	6.44M	6.14M	6.59M	541.00K
	Net Debt
4.82M	3.91M	1.19M	5.16M	4.41M	-5.58M
	Total Liabilities
9.44M	7.75M	10.07M	8.76M	8.69M	1.77M
	Stockholders Equity
1.62M	4.36M	6.05M	2.59M	6.68M	13.56M
Cash Flow		Free Cash Flow
-7.46M	-10.77M	-9.01M	-6.08M	-9.01M	-3.86M
	Operating Cash Flow
-6.71M	-10.17M	-8.29M	-5.18M	-5.92M	-3.40M
	Investing Cash Flow
1.68M	-1.49M	-691.00K	1.25M	2.83M	4.58M
	Financing Cash Flow
5.03M	8.25M	13.42M	2.56M	-804.00K	-181.00K

Oxford BioDynamics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.40
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:OBD, the sentiment is Negative. The current price of 0.4 is above the 20-day moving average (MA) of 0.37, below the 50-day MA of 0.41, and below the 200-day MA of 1.43, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 51.96 is Neutral, neither overbought nor oversold. The STOCH value of 41.84 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:OBD.

Oxford BioDynamics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IXI	62 Neutral	£10.43M	―	-13.85%	―	7.27%	39.64%
AREC	59 Neutral	£16.42M	―	-137.62%	―	10.50%	-9.60%
APTA	54 Neutral	£6.87M	―	-99.43%	―	17.39%	96.02%
Sector *	54 Neutral	$5.31B	3.26	-45.10%	2.79%	16.76%	0.02%
OBD	50 Neutral	£7.83M	―	-222.16%	―	24.71%	38.28%
FAB	44 Neutral	£7.56M	―	-129.49%	―	14.12%	78.16%

Oxford BioDynamics Corporate Events

Oxford BioDynamics’ Oxford Lab Achieves UKAS Accreditation for EpiSwitch® Tests

Oxford BioDynamics has announced that its Oxford-based laboratory has been accredited by the United Kingdom Accreditation Service (UKAS) under the ISO 15189 standard, allowing it to conduct EpiSwitch® Clinical Tests in the UK. This accreditation marks a significant milestone for the company, as it enhances the turnaround time for test results and supports the company’s strategy to centralize its clinical testing operations in the UK. The successful validation of the EpiSwitch Checkpoint Inhibitor Response Test (CiRT) in the UK lab is expected to benefit cancer patients by reducing the time taken to receive test results, thereby strengthening the company’s position in the diagnostics industry and its relationship with partners like Bupa UK.

Oxford BioDynamics Director Increases Stake, Signaling Confidence

Oxford BioDynamics announced that Non-Executive Director Peter Presland has purchased 3,398,553 ordinary shares, representing approximately 0.17% of the company’s issued share capital. This transaction, conducted on the London Stock Exchange, highlights insider confidence in the company’s future prospects and could positively influence stakeholder perceptions and market positioning.

Oxford BioDynamics CFO Executes Share Transfer

Oxford BioDynamics Plc announced a transaction involving its CFO, Paul Stockdale, who transferred 791,176 ordinary shares into his ISA through a sale and repurchase process. This transaction, conducted on the London Stock Exchange, leaves Stockdale with a beneficial interest in 3,077,919 shares, representing 0.16% of the company’s issued share capital. This move is part of routine financial management and does not indicate any significant change in company operations or strategy.

Oxford BioDynamics Successfully Passes AGM Resolutions

Oxford BioDynamics Plc announced the successful passing of all resolutions at its Annual General Meeting. This development underscores the company’s continued commitment to advancing precision medicine through its innovative diagnostic tests, potentially enhancing its market position and stakeholder confidence.

Oxford BioDynamics Strengthens Board with New Appointment

Oxford BioDynamics has announced the appointment of Peter Presland as a Non-Executive Director and Chair of the Audit Committee, succeeding Matthew Wakefield. Presland brings extensive experience in business management and corporate governance, which is expected to enhance the board’s independence and governance capabilities. This strategic board change is anticipated to positively impact the company’s operational and governance structure, potentially benefiting stakeholders by strengthening the company’s leadership and oversight.

Oxford BioDynamics Announces Change in Major Holdings

Oxford BioDynamics PLC has announced a change in its major holdings, with Spreadex LTD acquiring or disposing of financial instruments, resulting in a shift in voting rights. The transaction has led to a decrease in the total percentage of voting rights held by Spreadex LTD, which could impact the company’s influence on corporate decisions and its strategic positioning within the industry.

Oxford BioDynamics Expands Partnership with Bupa UK for Prostate Cancer Test Coverage

Oxford BioDynamics has expanded its partnership with Bupa UK insurance to include coverage for its EpiSwitch® PSE prostate cancer test. This strategic agreement enhances access to the PSE test for Bupa’s 3.9 million customers, particularly those with raised PSA levels but no high-risk factors or symptoms. The PSE test, known for its high accuracy and positive predictive value, aims to improve early prostate cancer diagnosis and reduce unnecessary procedures, aligning with Bupa’s commitment to advanced cancer care.